LUNGHI, Barbara
 Distribuzione geografica
Continente #
NA - Nord America 7.712
AS - Asia 3.761
EU - Europa 2.048
SA - Sud America 586
Continente sconosciuto - Info sul continente non disponibili 145
AF - Africa 96
OC - Oceania 5
Totale 14.353
Nazione #
US - Stati Uniti d'America 7.533
SG - Singapore 1.373
CN - Cina 902
VN - Vietnam 452
BR - Brasile 437
DE - Germania 371
IT - Italia 368
UA - Ucraina 330
HK - Hong Kong 316
GB - Regno Unito 214
TR - Turchia 186
FR - Francia 126
FI - Finlandia 125
BD - Bangladesh 124
SE - Svezia 114
JP - Giappone 113
PL - Polonia 100
CA - Canada 97
RU - Federazione Russa 78
IN - India 76
ID - Indonesia 56
MX - Messico 56
AR - Argentina 51
NL - Olanda 51
BE - Belgio 35
ZA - Sudafrica 33
IQ - Iraq 31
EC - Ecuador 26
ES - Italia 22
PK - Pakistan 22
CO - Colombia 18
CZ - Repubblica Ceca 18
MY - Malesia 17
AT - Austria 16
VE - Venezuela 16
PH - Filippine 14
CH - Svizzera 13
LT - Lituania 13
CL - Cile 12
DZ - Algeria 12
JO - Giordania 10
MA - Marocco 10
PY - Paraguay 10
SA - Arabia Saudita 9
GR - Grecia 8
IR - Iran 8
RO - Romania 8
NP - Nepal 7
TN - Tunisia 7
UZ - Uzbekistan 7
JM - Giamaica 6
KE - Kenya 6
PE - Perù 6
UY - Uruguay 6
AU - Australia 5
ET - Etiopia 5
IE - Irlanda 5
PT - Portogallo 5
AL - Albania 4
CI - Costa d'Avorio 4
IL - Israele 4
LB - Libano 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
BG - Bulgaria 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
KR - Corea 3
KW - Kuwait 3
NO - Norvegia 3
OM - Oman 3
PR - Porto Rico 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
AZ - Azerbaigian 2
BH - Bahrain 2
BM - Bermuda 2
BY - Bielorussia 2
CR - Costa Rica 2
EU - Europa 2
HU - Ungheria 2
SI - Slovenia 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
Totale 14.193
Città #
Singapore 846
Ashburn 830
Woodbridge 596
Fairfield 594
San Jose 457
Houston 402
Chandler 369
Santa Clara 351
Jacksonville 345
Hong Kong 309
Beijing 286
Seattle 264
New York 256
Ann Arbor 240
Dallas 224
Wilmington 215
Cambridge 194
Ho Chi Minh City 166
Council Bluffs 150
Tokyo 108
Ferrara 102
Izmir 102
Munich 101
Hanoi 99
Nanjing 99
Warsaw 96
Los Angeles 95
Boardman 93
Princeton 85
The Dalles 77
Lauterbourg 73
San Diego 62
Milan 58
São Paulo 47
Orem 45
Shanghai 40
Helsinki 39
Jakarta 39
Chicago 37
Dearborn 37
Buffalo 36
Shenyang 36
London 35
Mexico City 35
Brussels 34
Toronto 32
Bremen 31
Hefei 30
Tianjin 26
Hebei 24
Frankfurt am Main 23
Phoenix 23
Chennai 22
Turku 22
Brooklyn 21
Johannesburg 21
Rome 21
Jiaxing 20
Nanchang 19
Nuremberg 19
Montreal 18
Redwood City 18
Changsha 16
Da Nang 16
Haiphong 16
Amsterdam 15
Denver 15
Stockholm 15
San Francisco 14
Brno 13
Kunming 13
Mountain View 13
Norwalk 13
Atlanta 12
Auburn Hills 12
Des Moines 12
Düsseldorf 12
Manchester 12
Mcallen 12
Baghdad 11
Curitiba 11
Dong Ket 11
Falkenstein 11
Moscow 11
Vienna 11
Belo Horizonte 10
Hangzhou 10
Poplar 10
Columbus 9
Ottawa 9
Redmond 9
Amman 8
Ankara 8
Biên Hòa 8
Boston 8
Charlotte 8
Guayaquil 8
Jinan 8
Kuala Lumpur 8
Lahore 8
Totale 9.620
Nome #
C6orf10 low-frequency and rare variants in italian multiple sclerosis patients 364
An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis 309
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 294
A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders 265
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 260
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family 259
Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis 256
A novel mutation (Leu817Pro) causing type 2A von Willebrand disease 252
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 252
A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects 251
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype 249
Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants 248
A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the italian population 226
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 225
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation 224
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 223
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 223
Cis-segregation of c.1171c>t stop codon (p.r391*) in serpinc1 gene and c.1691g>a transition (p.r506q) in f5 gene and selected gwas multilocus approach in inherited thrombophilia 222
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 215
FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers 212
A new factor V gene polymorphism (His 1254 Arg) present in subjects of African origin mimics the R2 polymorphism (His 1299 Arg) 211
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 205
Performance prediction models based on anthropometric, genetic and psychological traits of Croatian sprinters 205
A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject 202
Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma 201
The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis 200
Interaction of occupational posture, lifestyle and genetic components of thrombophilia 199
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 197
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 196
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome 193
An Italian Family with a Novel Mutation Causing Type 2A von Willebrand Disease and with Reduced Levels of von Willebrand Factor not Linked with the von Willebrand Factor Gene. 192
An underestimated combination of opposites resulting in enhanced thrombotic tendency 186
The factor VIII D I24I E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels 184
Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism 182
Factor V gene mutations (R2 gene) are associated with coronary artery disease inelderly people 181
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 174
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 168
Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? 164
New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V leiden mutation in Mediterranean populations and Indians 164
Factor V markers for the detection of genetic components of APC resistance in venous thrombosis 164
Hemostasis gene expression of the internal jugular and saphenous veins 160
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro- progestins 154
Modulation of factor V levels in plasma by polymorphisms in the C2 domain 154
Factor V markers for the detection of genetic components of APC resi stance in venous thrombosis. 151
Risks factors for highly unstable response to oral anticoagulation: a case-control study 150
Venous thromboembolism in young women - Role of thrombophilic mutations and oral contraceptive use 150
Novel phenotype and gamma-glutamyl carboxylase mutations in combined deficiency of vitamin K-dependent coagulation factors 150
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 149
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 146
Factor V Levels in a Cohort of Patients Eligible for Oral Anticoagulant Therapy. 144
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 144
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis 143
Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients 142
CMR+ Factor V deficiency Arg2080Cys: A model to investigate altered C2 domain-membrane interaction. 141
Functional genetics 140
Resistance to activated protein C in healthy women taking oral contraceptives 139
Phenotype and genotype expression in pseudohomozygous factor V-LEIDEN - The need for phenotype analysis 138
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299 Arg substitutions in factor V 136
Molecular basis of coagulation factor V deficiency caused by the R1698W inter-domain mutation. 134
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease 132
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation 129
In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A 127
Polimorfismi funzionali e terapia anticoagulante 124
Increased Susceptibility to Proteases in Type 2A von Willebrand Disease Associated with two Novel Mutations (Val 867 Glu, Pro 864 His). 123
Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma 121
Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies 111
Contribution of low density lipoprotein receptor-related protein genotypes to coagulation factor VIII levels in thrombotic women 110
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 108
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 108
Whole-Exome Sequencing in a Family with an Unexplained Tendency for Venous Thromboembolism: Multicomponent Prediction of Low-Frequency Variant Deleteriousness and of Individual Protein Interaction 105
The asymptomatic carriership of thrombophilic defects is associated with frequent genotypes of the fibrinogen gene cluster. 105
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 103
Evaluation of FV mRNA to define the residual FV expression levels in severe FV deficiency 97
Expression and characterization of a factor V mutation (E1608K) detected in familial thrombophilia. 96
null 95
Studio di mutazioni in geni dell’emostasi. 91
Lesioni molecolari ricorrenti sono responsabili di difetti funzionali del fattore VII. 90
Detection of New Polymorphic Markers in the Factor V Gene. 90
null 88
Studio di Mutazioni in Geni dell'Emostasi. 86
Selected cell receptor genotypes differentially modulate the ABO blood group influence on Factor VIII levels in severe aortic stenosis 83
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency 78
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors 68
Association of membranous nephropathy with familial resistance to activated protein C 66
Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels. 64
null 63
Factor V Kuwait alias factor V R3: A rare polymorphism of uncertain functional significance 54
Genetic components in factor VIII receptors for individual and genotype-modeled hemophilia A treatment 32
Genetic determinants of activated factor VII-antithrombin plasma levels and mortality in patients with coronary artery disease 23
Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited 21
Totale 14.353
Categoria #
all - tutte 66.039
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.039


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022807 0 87 47 71 50 18 54 47 21 59 83 270
2022/2023902 93 78 24 109 130 130 67 76 100 15 46 34
2023/2024563 34 39 18 20 36 183 9 26 17 7 13 161
2024/20251.870 44 31 172 66 243 169 46 77 316 219 275 212
2025/20265.510 524 222 523 704 758 356 620 311 547 537 277 131
2026/2027317 153 164 0 0 0 0 0 0 0 0 0 0
Totale 14.353